Show simple item record

dc.contributor.authorGüleç Yılmaz, Seda
dc.contributor.authorYenilcek, Faruk
dc.contributor.authorYıldırım, Asıf
dc.contributor.authorAkdeniz, Fatma Tuba
dc.contributor.authorDalan, Altay Burak
dc.contributor.authorBarut, Zerrin
dc.contributor.authorİsbir, Turgay
dc.date.accessioned2022-06-21T05:59:29Z
dc.date.available2022-06-21T05:59:29Z
dc.date.issued2021
dc.identifier.citationGüleç Yılmaz, S., Yenilcek, F., Yıldırım, A., Akdeniz, F. T., Dalan, A. B., Barut, Z. & İsbir, T. (2021). The role of Kallikrein10 (KLK10) polymorphism in prostate cancer susceptibility. Urology Journal, 19(1), 41-44.en_US
dc.identifier.issn1735-1308
dc.identifier.urihttp://hdl.handle.net/20.500.12566/1198
dc.description.abstractPurpose: The present study aims to investigate the potential role of Kallikrein 10 (KLK10) genotype and allele frequencies in predisposition to prostate cancer. Materials and methods: KLK10 (rs7259451) gene polymorphisms were determined by real-time polymerase chain reaction analysis in patients with prostate cancer (n=69) and controls (n=76). Results: KLK10 gene frequencies were significantly different in the case and control groups (P = .028). GG carriers were significantly higher in the control group (P = .034), whereas TT carriers were higher in the prostate cancer group (P = .033). Furthermore, The patients with GG genotype had the lowest PSA levels while TT carriers had the highest (P = .005). Conclusion: According to the results, we suggested that carrying variant T allele and also carrying homozygote TT genotype could be a potential risk, while ancestral homozygote GG genotype and G allele are risk reducing factors for prostate cancer.en_US
dc.description.sponsorshipNo sponsoren_US
dc.language.isoengen_US
dc.publisherUrology Journalen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectKLK10 geneen_US
dc.subjectPolymorphismen_US
dc.subjectProstate cancertr_TR
dc.subjectProstat kanseritr_TR
dc.subjectPSAen_US
dc.subjectrs7259451en_US
dc.titleThe role of Kallikrein10 (KLK10) polymorphism in prostate cancer susceptibilityen_US
dc.typeinfo:eu-repo/semantics/articleen_US
dc.relation.publicationcategoryInternational publicationen_US
dc.identifier.wosWOS:000773355300005
dc.identifier.scopus2-s2.0-85127730099
dc.identifier.volume19
dc.identifier.issue1
dc.identifier.startpage41
dc.identifier.endpage44
dc.contributor.orcid0000-0002-6289-5562 [Barut, Zerrin]
dc.contributor.abuauthorBarut, Zerrin
dc.contributor.yokid330764 [Barut, Zerrin]
dc.contributor.ScopusAuthorID57223116503 [Barut, Zerrin]
dc.identifier.PubMedID34089177
dc.identifier.doi10.22037/uj.v18i.6425


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record